Revolution Medicines (RVMD) Income towards Parent Company: 2019-2025
Historic Income towards Parent Company for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to -$305.2 million.
- Revolution Medicines' Income towards Parent Company fell 95.28% to -$305.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$960.9 million, marking a year-over-year decrease of 69.46%. This contributed to the annual value of -$600.0 million for FY2024, which is 37.51% down from last year.
- Latest data reveals that Revolution Medicines reported Income towards Parent Company of -$305.2 million as of Q3 2025, which was down 23.17% from -$247.8 million recorded in Q2 2025.
- Over the past 5 years, Revolution Medicines' Income towards Parent Company peaked at -$37.2 million during Q1 2021, and registered a low of -$305.2 million during Q3 2025.
- In the last 3 years, Revolution Medicines' Income towards Parent Company had a median value of -$156.3 million in 2024 and averaged -$163.9 million.
- Data for Revolution Medicines' Income towards Parent Company shows a maximum YoY plummeted of 185.87% (in 2023) over the last 5 years.
- Quarterly analysis of 5 years shows Revolution Medicines' Income towards Parent Company stood at -$52.7 million in 2021, then fell by 7.27% to -$56.5 million in 2022, then plummeted by 185.87% to -$161.5 million in 2023, then declined by 20.42% to -$194.5 million in 2024, then plummeted by 95.28% to -$305.2 million in 2025.
- Its Income towards Parent Company stands at -$305.2 million for Q3 2025, versus -$247.8 million for Q2 2025 and -$213.4 million for Q1 2025.